Previous 10 | Next 10 |
AXGT has promising gene therapy results in Parkinson's Disease. If future clinical results mimic the early ones, AXGT could have an addressable market of over $7.5 billion. Trading at an enterprise value of $143M, the risk reward ratio is enticing. Nonetheless, investors sho...
Neurocrine presents encouraging three-year data for Parkinson’s treatment Neurocrine Biosciences Inc. ( NBIX ) reported that its data from PD-1101 study has demonstrated sustained improvement in motor function in patients with Parkinson’s disease. This Phase Ib open-label, th...
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the addition of Nancy Vitale as an independent director to i...
CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Michelle Quinn Smith as Chief Human Resou...
I had previously expressed my concern that Neurocrine ( NBIX ) shares could remain weak given a lack of thesis-changing data catalysts on the horizon, and the shares have fallen another 17% since my last update. I see nothing wrong with the business, but the quality of the Ingrezza business ...
Collaboration partners, Neurocrine Biosciences (NASDAQ: NBIX) and Voyager Therapeutics (NASDAQ: VYGR) announced data from an early stage clinical trial with Parkinson's disease patients and NBIb-1817, an experimental gene therapy. Three years after a single administration, 14 out of...
Neurocrine Biosciences ( NBIX -3.8% ) and Voyager Therapeutics ( VYGR -1.5% ) announced data from Phase Ib (PD-1101) three-year efficacy and safety study, demonstrating that a one-time treatment with NBIb-1817 (VY-AADC) showed sustained improvement in motor function including...
-- Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 -- NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including Greater “On” Time without Troublesome Dyskinesia and Reduction in Unified ...
New Phase 1b Data of Investigational Gene Therapy Compound, VY-AADC (NBIb-1817), Evaluating Three-Year Safety and Clinical Outcomes in Patients with Advanced Parkinson’s Disease Voyager to Participate in Upcoming September Investor Conferences CAMBRIDGE, Mass., Sept. 03, 202...
BioMarin ( BMRN ) received a complete response letter or CRL for their hemophilia A gene therapy Valrox last week. As a result, the earliest commercial launch is now in 2023. Audentes ( ALPMF ) provided an update on their please 3 neuromuscular ASPIRO clinical trial indicating a third pati...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...